U.S. Markets closed

Biota's influenza drug fails in mid-stage study

Aug 1 (Reuters) - Biota Pharmaceuticals Inc said its experimental influenza drug failed to meet the main goal in a mid-stage study.

The drug, Laninamivir octanoate, is undergoing development to treat influenza A and B infections.

(Reporting by Natalie Grover in Bangalore; Editing by Savio D'Souza)